A nodule is not a diagnosis
What should happen after a screening scan finds a lung nodule

Lung cancer screening has been argued over almost entirely at the front door: who qualifies, who is invited, how the image is read. The decisive question comes later — the moment a scan finds something — and it is not whether to operate to find out what it is, but whether anyone should be operating to find out at all.

Screening fills clinics with nodules

A screening programme does not mainly find cancers. It finds nodules — most of them benign — in people who feel well. That is the point: to catch the few early enough to cure. But it changes the surgeon's job. The volume of small, indeterminate shadows reaching thoracic clinics has risen, and with it the oldest temptation in the specialty: to resolve uncertainty in theatre. For decades, a nodule with a high suspicion of cancer was often settled by removing it and finding out. Screening makes that reflex dangerous at scale — the more nodules you chase to the operating table, the more healthy lung you take from people who never had cancer. Reporting this year in The Annals of Thoracic Surgery, the Society of Thoracic Surgeons published its first expert consensus on precisely this problem — not how to find nodules, but what should happen to the patient once one is found.

A nodule is not a diagnosis

The consensus is unambiguous. Wherever possible, a lobe should not be removed to establish a diagnosis; pneumonectomy without tissue confirmation is ruled out altogether; and where an operation is used to diagnose, it should take the smallest amount of lung that answers the question — a wedge, not an anatomical resection. Holding this together is one metric: the benign resection rate — the proportion of screen-detected patients who have lung removed for what proves benign. In the original trials, NLST and NELSON, that figure ran at 24 to 28 per cent — nearly one operation in four for a benign result. The consensus sets the modern benchmark below 10 per cent, and a UK programme has already shown what is reachable: the Manchester Lung Health Check reported 2.5 per cent. The gap between those numbers is not surgical skill. It is whether you biopsy first.

The biopsy got better — and far safer

For years the case for operating to diagnose rested on a real limitation: bronchoscopy could not reliably reach a small nodule in the outer lung, and the alternative — a CT-guided needle through the chest wall — risked collapsing it. Robotic navigational bronchoscopy has changed that calculus. McNierney and colleagues, reporting in Lung Cancer this year, compared shape-sensing robotic bronchoscopy with CT-guided biopsy in 638 patients. The diagnostic yield was the same — 84 against 80 per cent, no significant difference — but the harm was not close: pneumothorax in 1.4 per cent of the robotic group against 29.5 per cent after the needle, and pulmonary haemorrhage in 0.2 against 14 per cent. The consensus cites a randomised comparison pointing the same way: 0.8 per cent pneumothorax after robotic navigation against 11.5 per cent after a transthoracic needle. The honest trade-off is time — the robotic procedure took around ten minutes longer; for a diagnosis at a fraction of the harm, most patients would take that trade. Where the obstacle is divergence between the scan and the ventilated lung, two adjuncts increasingly close it: rapid on-site evaluation to confirm the sample at the table, and cone-beam CT to confirm the instrument is in the lesion. In its first year, our robotic bronchoscopy service at Guy's performed over 650 of these procedures; this is established practice, not a pilot.

The sample has to do more than name the cancer

There is a second reason the route to diagnosis matters, unrelated to comfort. A lung cancer diagnosis is no longer complete when the cell type is known: treatment increasingly turns on molecular profiling — the driver mutations that decide whether a patient has targeted therapy, immunotherapy or chemotherapy — and that needs enough tissue. In the same study, the robotic samples were more often adequate for molecular analysis — 90 against 79 per cent — and patients reached treatment three weeks sooner. A biopsy that is safer, more often sufficient for molecular testing, and quicker to treatment is doing three jobs at once. Frozen section — examining tissue during the operation itself — can do none of them without first committing the patient to theatre and an anaesthetic.

Standards, and the UK pathway

The consensus does more than argue for biopsy first; it puts numbers on what the pathway should deliver: complication thresholds for each diagnostic step, minimally invasive surgery in preference to thoracotomy, and definitive treatment within twelve weeks of the scan that prompted it. It is a United States document, written around United States screening, and should be read here as a template to translate, not transplant. The translation is not hard: two of its strongest anchors are British — the VIOLET trial, which established minimally invasive lobectomy as standard, and Manchester's benign resection rate. As the NHS Targeted Lung Health Checks grow into a national programme, the same metrics deserve to be tracked here — how often a screen-detected patient has benign lung removed, how often a biopsy causes harm, how long the pathway takes from scan to treatment. Those are the numbers that decide whether screening keeps its promise — and they belong to the part the patient never sees: the work-up of the nodule before anyone reaches for a scalpel.

What finding more is worth

Screening's case rests on a single claim: that finding lung cancer earlier saves lives. It does. But the benefit is not banked at the moment of detection — it is banked, or lost, in everything that follows. A programme that finds more cancers while removing more benign lungs, or that delays the cancers it does find, gives back at the back door what it gained at the front. The quiet shift in the surgeon's role is the measure of a maturing pathway: less the person who operates to find out, more the one who ensures each patient has the fewest, safest and most informative steps before anyone operates at all. Finding the nodule was always going to be the easy part.

← Back to the Journal